Patient Blood Management Charité (PBM-Charité): ): Cohort Study About Structured Detection, Differentiated Diagnostics and Therapy of Preoperative Anemia and Use of Machine Autotransfusion in Elective Interventions
The aim of patient blood management is to reduce the risks of perioperative anemia- and transfusion-associated complications by limiting the use and the need for allogeneic blood transfusion.
⁃ age ≥ 18 years
⁃ male and female patients
⁃ patients eligible for inclusion: by the patient, preoperatively
⁃ patients who are insured with BARMER
⁃ patients with preoperative anemia and an elective (N5) surgical intervention with a probability of transfusion \> 10%
‣ additionally for the use of MAT:
⁃ indication of machine autotransfusion
⁃ high blood loss (\> 500ml / 10-20 % of estimated blood volume) beside of indication interventions (surgery under dual platelet inhibition, high individual bleeding risk, special antibodies / rare blood group, rejection of allogeneic blood)
• Data since September 2021-February 2024 of patients who are not insured with BARMER with elective (N5) interventions with a transfusion probability \> 10% (indication list) with a preoperatively existing anemia
‣ additionally for the use of MAT:
⁃ indication of machine autotransfusion
⁃ high blood loss (\> 500ml / 10-20 % of estimated blood volume) beside of indication interventions (surgery under dual platelet inhibition, high individual bleeding risk, special antibodies / rare blood group, rejection of allogeneic blood)